Literature DB >> 12439219

Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor gamma gene with breast cancer and body mass.

Asli Memisoglu1, Susan E Hankinson, JoAnn E Manson, Graham A Colditz, David J Hunter.   

Abstract

A principal hypothesized mechanism underlying breast carcinogenesis involves oestrogen-induced cell proliferation. In addition to its well-established role in the transcriptional regulation of genes required for adipocyte differentiation, the peroxisome proliferator-activated receptor gamma (PPARgamma) may be involved in transcriptional down-regulation of aromatase, a key enzyme in oestrogen biosynthesis. Furthermore, specific agonists for PPARgamma induce differentiation and suppress markers of malignancy in breast cancer cells in vitro. We investigated the association of the Pro12Ala PPARgamma polymorphism with breast cancer in a case-control study nested within the prospective Nurses' Health Study. Included were 725 incident cases of breast cancer diagnosed after blood collection through 1996 and 953 matched controls. In addition to breast cancer, the association of the PPARgamma Pro12Ala polymorphism with breast cancer risk factors, body mass index (BMI), weight gain since age 18 years, plasma hormones [oestrone sulphate, oestrone, oestradiol, androstenedione, testosterone, dehydroepiandrosterone (DHEA) and DHEA sulphate] and plasma lipids (total cholesterol and high density lipoprotein) was analysed. No significant association was observed between PPARgamma Pro12Ala polymorphism and either incident breast cancer (odds ratio = 1.08, 95% confidence interval = 0.85-1.38 for Ala allele carriers compared to non-carriers), plasma hormones, plasma cholesterol, BMI, weight gain since age 18 years or waist-to-hip ratio. To our knowledge, this is the first study to investigate the role of the Pro12Ala PPARgamma polymorphism in cancer. We did not find evidence to support a role for this polymorphism in breast cancer susceptibility. Furthermore, similar to others, we did not find evidence to suggest that Pro12Ala PPARgamma polymorphism is directly associated with body mass or weight gain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439219     DOI: 10.1097/00008571-200211000-00003

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  10 in total

1.  Genetic variation in peroxisome proliferator-activated receptor gamma, soy, and mammographic density in Singapore Chinese women.

Authors:  Eunjung Lee; Chris Hsu; David Van den Berg; Giske Ursin; Woon-Puay Koh; Jian-Min Yuan; Daniel O Stram; Mimi C Yu; Anna H Wu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-01       Impact factor: 4.254

2.  Age- and gender-dependent heterogeneous proportion of variation explained by SNPs in quantitative traits reflecting human health.

Authors:  Dain Lee; Chaeyoung Lee
Journal:  Age (Dordr)       Date:  2015-02-21

3.  Genetic variation in TNFα, PPARγ, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort.

Authors:  Catherine Duggan; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Stephanie George; Rachel Ballard; Marian L Neuhouser; Anne McTiernan
Journal:  Breast Cancer Res Treat       Date:  2017-12-18       Impact factor: 4.872

4.  PPAR gamma signaling exacerbates mammary gland tumor development.

Authors:  Enrique Saez; John Rosenfeld; Antonia Livolsi; Peter Olson; Eleuterio Lombardo; Michael Nelson; Ester Banayo; Robert D Cardiff; Juan Carlos Izpisua-Belmonte; Ronald M Evans
Journal:  Genes Dev       Date:  2004-03-01       Impact factor: 11.361

5.  Peroxisome proliferator-activated receptor gamma (PPARG) polymorphisms and breast cancer susceptibility: a meta-analysis.

Authors:  Weifeng Tang; Yuanmei Chen; Yafeng Wang; Haiyong Gu; Shuchen Chen; Mingqiang Kang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

6.  Peroxisome proliferator-activated receptor gamma (PPARG) rs1801282 C>G polymorphism is associated with cancer susceptibility in asians: an updated meta-analysis.

Authors:  Yafeng Wang; Yu Chen; Heping Jiang; Weifeng Tang; Mingqiang Kang; Tianyun Liu; Zengqing Guo; Zhiqiang Ma
Journal:  Int J Clin Exp Med       Date:  2015-08-15

7.  ASSOCIATION OF THE HUMAN PPARγ2 PRO12ALA POLYMORPHISM WITH OBESITY IN A POPULATION FROM TURKEY.

Authors:  M A Sözen; M U Özcan; M Çıldır; I H Doğru; A G Aygök; K Ü Balkan
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

8.  Peroxisome Proliferator-Activated Receptor Gamma Pro12Ala/C161T Genotypes and Risky Haplotype Altering Risk of Breast Cancer: A Turkish Case-Control Study.

Authors:  Esra Unal; Ezgi Irmak Aslan; Tulin Ozturk; Ozlem Kurnaz Gomleksiz; Ozlem Kucukhuseyin; M Bora Tuzuner; M Fatih Seyhan; Oguz Ozturk; Hulya Yilmaz Aydogan
Journal:  Biochem Genet       Date:  2021-04-24       Impact factor: 1.890

9.  The relationship between IGF2BP2 and PPARG polymorphisms and susceptibility to esophageal squamous-cell carcinomas in the eastern Chinese Han population.

Authors:  Hao Qiu; Yafeng Wang; Mingqiang Kang; Hao Ding; Chao Liu; Weifeng Tang; Zhenzhou Xiao; Yu Chen
Journal:  Onco Targets Ther       Date:  2017-11-21       Impact factor: 4.147

10.  Relationship of PPARG, PPARGC1A, and PPARGC1B polymorphisms with susceptibility to hepatocellular carcinoma in an eastern Chinese Han population.

Authors:  Sheng Zhang; Jiakai Jiang; Zhan Chen; Yafeng Wang; Weifeng Tang; Yu Chen; Longgen Liu
Journal:  Onco Targets Ther       Date:  2018-08-08       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.